Navigation Links
Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference

SAN DIEGO, Sept. 24 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the Fifth Annual JMP Securities Healthcare Conference.  The details are as follows:  Date:  Tuesday, September 28, 2010Time:  11:00am (EDT)Location: New York Palace HotelSpeaker: Graham Cooper, Chief Financial OfficerAbout Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave®.  The Company's second product, Empatic™, has completed Phase 2 clinical development.  Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches.  Further information about the Company can be found at

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
2. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
3. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
4. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
5. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
6. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
7. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
8. Echo Therapeutics to Present at the JMP Securities Healthcare Conference
9. Precision Therapeutics President and CEO Sean McDonald Recognized as a Leading Business Executive and Recipient of 2010 Pacesetters Award
10. Echo Therapeutics Initiates Needle-Free Biosensor Program for Continuous Lactate Monitoring
11. Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
Post Your Comments:
(Date:10/11/2017)...  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided ... Piedras, Puerto Rico , where the ... Following a comprehensive onsite ... structural damage, temporary loss of power and minimal water ... manufacturing operations have resumed, and the company expects to ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
Breaking Medicine News(10 mins):